Could a new drug free kidney transplant patients from lifelong pills?

NCT ID NCT05806749

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tests whether the drug belumosudil, given with donor stem cells, can help the body accept a new kidney without needing strong anti-rejection drugs for life. Sixteen adults with end-stage kidney disease will receive a living donor kidney and stem cell transplant, plus a short course of immune-suppressing medicines. The main goal is to see if this approach is safe and allows patients to stop taking tacrolimus and mycophenolate within 18 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
belumosudil (KD025) combined with donor stem cells and immune cells
What this could lead to
If successful, this could allow kidney transplant recipients to take fewer or no lifelong anti-rejection drugs, reducing side effects and improving quality of life.
What could go wrong
This is a very early, small pilot study (16 people) focused on safety. It may not show lasting tolerance, and the conditioning regimen carries risks like infection or graft rejection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of California, Los Angeles

    Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.